Ocular Therapeutix (OCUL) Gains from Investment Securities (2013 - 2026)
Ocular Therapeutix (OCUL) recorded quarterly Gains from Investment Securities of $419676.0 in Q1 2026, down 97.71% quarter-over-quarter from $18.3 million in Q4 2025, and down 59.98% on a YoY basis from $1.0 million in Q1 2025.
Ocular Therapeutix (OCUL) Gains from Investment Securities (2013 - 2026) Analysis & Trends
Ocular Therapeutix's Gains from Investment Securities history runs 14 years deep, the most recent figure standing at $419676.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 59.98% year-over-year to $419676.0; the TTM figure through Mar 2026 stood at $419676.0 (down 59.98% YoY), while the FY2025 annual figure was $1.7 million, down 91.58% from the prior year.
- Gains from Investment Securities was $419676.0 for Q1 2026 at Ocular Therapeutix, down from $18.3 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $19.9 million in Q4 2024 to a low of $29000.0 in Q2 2025.
- Historically, Gains from Investment Securities has averaged $3.2 million across 5 years, with a median of $862839.5 in 2024.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities surged 7158.28% in 2024, then sank 96.04% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $212150.0 in 2022, then grew by 29.15% to $274000.0 in 2023, then soared by 7158.28% to $19.9 million in 2024, then dropped by 7.74% to $18.3 million in 2025, then tumbled by 97.71% to $419676.0 in 2026.
- The last three Gains from Investment Securities figures came in at $419676.0 (Q1 2026), $18.3 million (Q4 2025), and $262429.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ocular Therapeutix | 2.12 Bn | 2.12 Bn | 9.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 419,676.00 |
| Mar 31, 2026 | 419,676.00 |
| Dec 31, 2025 | 18.35 Mn |
| Dec 31, 2025 | 18.35 Mn |
| Sep 30, 2025 | 262,429.00 |
| Sep 30, 2025 | 262,429.00 |
| Jun 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Mar 31, 2025 | 1.05 Mn |
| Mar 31, 2025 | 1.05 Mn |
| Dec 31, 2024 | 19.89 Mn |
| Dec 31, 2024 | 19.89 Mn |
| Sep 30, 2024 | 1.84 Mn |
| Sep 30, 2024 | 1.84 Mn |
| Jun 30, 2024 | 731,580.00 |
| Jun 30, 2024 | 731,580.00 |
| Mar 31, 2024 | 994,099.00 |
| Mar 31, 2024 | 994,099.00 |
| Dec 31, 2023 | 274,000.00 |
| Dec 31, 2023 | 274,000.00 |